IGN002

BIOLOGICAL2 trials

Sponsors

Spectrum Pharmaceuticals, Inc

Conditions

NHLNon-Hodgkin Lymphoma

Phase 1

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

TerminatedNCT02519270

Spectrum Pharmaceuticals, IncNon-Hodgkin Lymphoma

Start: 2016-05-01End: 2018-05-04Updated: 2022-03-11

A Study of IGN002 for Refractory NHL

WithdrawnNCT02847949

Spectrum Pharmaceuticals, IncNHL

Start: 2021-01-31End: 2025-12-31Updated: 2022-03-11

Related Papers

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma

Blood2020-11-041 citations

In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells

Blood2019-11-131 citations

Antibody-interferon-alpha fusion protein (IGN002) for the treatment of b-cell non-Hodgkin lymphomas: A phase 1, first-in-human, dose-escalation trial.

Journal of Clinical Oncology2016-05-206 citations

Ibrutinib plus anti-CD20-interferon alpha fusion protein for treatment of B cell lymphomas.

Journal of Clinical Oncology2016-05-20